219 related articles for article (PubMed ID: 9454653)
1. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
[TBL] [Abstract][Full Text] [Related]
2. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
3. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
Merbs SL; Sidransky D
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):779-83. PubMed ID: 10067984
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
5. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
[TBL] [Abstract][Full Text] [Related]
6. [Investigations to the influence of tumor supressor gene p16 inactivation on the prognosis of head and neck squamous cell carcinoma].
Koscielny S; V Eggeling F; Dahse R
Laryngorhinootologie; 2004 Jun; 83(6):374-80. PubMed ID: 15197677
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A gene inactivation in epithelial sporadic ovarian cancer.
Niederacher D; Yan HY; An HX; Bender HG; Beckmann MW
Br J Cancer; 1999 Aug; 80(12):1920-6. PubMed ID: 10471040
[TBL] [Abstract][Full Text] [Related]
8. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
9. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma.
Bazan V; Zanna I; Migliavacca M; Sanz-Casla MT; Maestro ML; Corsale S; Macaluso M; Dardanoni G; Restivo S; Quintela PL; Bernaldez R; Salerno S; Morello V; Tomasino RM; Gebbia N; Russo A
J Cell Physiol; 2002 Sep; 192(3):286-93. PubMed ID: 12124774
[TBL] [Abstract][Full Text] [Related]
11. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
[TBL] [Abstract][Full Text] [Related]
12. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
[TBL] [Abstract][Full Text] [Related]
13. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers.
Sanchez-Cespedes M; Decker PA; Doffek KM; Esteller M; Westra WH; Alawi EA; Herman JG; Demeure MJ; Sidransky D; Ahrendt SA
Cancer Res; 2001 Mar; 61(5):2092-6. PubMed ID: 11280771
[TBL] [Abstract][Full Text] [Related]
14. DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas.
Wu CL; Roz L; McKown S; Sloan P; Read AP; Holland S; Porter S; Scully C; Paterson I; Tavassoli M; Thakker N
Genes Chromosomes Cancer; 1999 May; 25(1):16-25. PubMed ID: 10221335
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma.
Ahrendt SA; Eisenberger CF; Yip L; Rashid A; Chow JT; Pitt HA; Sidransky D
J Surg Res; 1999 Jun; 84(1):88-93. PubMed ID: 10334895
[TBL] [Abstract][Full Text] [Related]
16. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
17. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.
Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck.
González MV; Pello MF; López-Larrea C; Suárez C; Menéndez MJ; Coto E
Clin Cancer Res; 1995 Sep; 1(9):1043-9. PubMed ID: 9816078
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation.
Muscarella P; Melvin WS; Fisher WE; Foor J; Ellison EC; Herman JG; Schirmer WJ; Hitchcock CL; DeYoung BR; Weghorst CM
Cancer Res; 1998 Jan; 58(2):237-40. PubMed ID: 9443399
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
